| CEO Name | Siggi Olafsson |
| Nationality | Iceland |
| Net Worth Estimation | $20 million |
Siggi Olafsson, CEO of Mallinckrodt Pharmaceuticals, has an estimated net worth of $20 million due to his executive compensation, stock awards, and leadership roles at major pharmaceutical companies like Actavis and Hikma. His accumulated wealth reflects both substantial base salaries and performance-based bonuses over his career in the pharma industry.
Siggi Olafsson, CEO of Mallinckrodt Pharmaceuticals, has an estimated net worth of $20,000,000, which is 12.5% of the maximum and 100% higher than the minimum estimated CEO net worth for the healthcare sector. His wealth places him in the lower-to-middle range compared to peers in the $10M-$90M net worth bracket.
Business Category: Healthcare
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD
Siggi Olafsson Performance in Mallinckrodt Pharmaceuticals
Siggi Olafsson, CEO of Mallinckrodt Pharmaceuticals, has demonstrated decisive leadership by streamlining operations and steering the company through financial restructuring. His decision-making focused on enhancing product portfolios and expanding market reach, resulting in improved revenue stability. Under Olafsson's direction, Mallinckrodt experienced strengthened operational performance and regained investor confidence.
Latest News
**Mallinckrodt and Endo Form $6.7B Specialty Pharma Giant, Led by CEO Siggi Olafsson**
Mallinckrodt Pharmaceuticals, led by CEO Siggi Olafsson, is merging with Endo International in a cash and stock deal to create a combined company valued at $6.7 billion, with Mallinckrodt shareholders owning 50.1% and the new entity planning to split off its generics business post-merger. Olafsson will serve as CEO of the merged company, which focuses on both branded specialty pharmaceuticals and generics after the planned spin-off.
Source: http://www.biopharmadive.com/news/endo-mallinckrodt-merger-deal-separate-generics-injectables/742417/